As described above, monalizumab is a humanised anti-NKG2A antibody which has been shown to enhance the activity of NK cells against various tumour cells and rescue CD8+ T cell function in combination with blockade of the PD-x axis (116). The gene discussed is KLRC1; the disease is neoplasm.